小麦谷物催化改善性结肠炎:抑制肠道炎症,调节肠道微生物群,恢复粘膜屏障的完整性
Tao Zhu1, Shi-Yue Sun2, Shuo-Xin Yang3
1School of Acu-Mox and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Journal of inflammation research
|September 18, 2025
概括
小麦谷物催化剂 (Wgm) 通过减少炎症和恢复肠道健康,有效地治疗小鼠的性结肠炎 (UC). 这种疗法调节肠道微生物组并加强肠道屏障,为UC管理提供了一种新的方法.
科学领域:
- 综合医学是一个整体的医学.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 小麦谷物催化剂 (Wgm) 是一种热刺激疗法,对于性结肠炎 (UC) 有着已知的益处.
- 在UC中Wgm的有效性背后的确切机制尚不清楚.
- 这项研究探讨了Wgm对UC小鼠模型中的结肠炎症,粘膜屏障和肠道微生物群的影响.
研究的目的:
- 在DSS诱导的UC小鼠模型中研究Wgm在特定针点 (中,天水,香州) 的治疗机制.
- 评估Wgm对结肠炎症细胞因子,肠道屏障功能和肠道微生物组合的影响.
- 为了阐明参与Wgm抗结肠炎作用的信号通路.
主要方法:
- 建立了德克斯硫酸盐 (DSS) 诱导的UC小鼠模型.
- 连续七天每天给目标针点服用Wgm.
- 通过体重,疾病活动指数 (DAI),结肠长度和组织病理学来评估治疗效果.
- 使用ELISA,IHC,WB和RT-PCR测量了炎症性细胞因子和屏障蛋白.
- 使用16S rRNA测序来表征肠道微生物群.
主要成果:
- 在UC小鼠中,Wgm显著改善了DAI得分,体重和结肠长度.
- Wgm抑制了TLR4/MyD88/NF-κB信号通路,减少了促炎性细胞因子 (IL-1β,IL-6,TNF-α) 和MPO,COX2.
- 通过降低损伤标志物的调节和提高保护性蛋白质 (MUC2,ZO-1,Occludin) 的调节,Wgm恢复了肠粘膜屏障功能.
- Wgm调节肠道微生物群的组成和多样性.
结论:
- 通过抑制TLR4/MyD88/NF-κB通路,Wgm可以缓解小鼠的大肠炎.
- WGM恢复了肠道粘膜屏障的完整性,并调节了肠道微生物组的概况.
- 这些发现突出了Wgm的多式疗效和改善UC的潜在机制.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
Inflammatory Bowel Disease I: Ulcerative Colitis
903
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
903
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
644
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439


